Omalizumab/Salbutamol

Dr. Christou: This is not the correct option for Amy at this time. Let me explain why. Omalizumab (anti-IgE therapy) is a biological agent reserved for Step 5 treatment of severe asthma with confirmed allergic sensitization and inadequate control on high-dose ICS-LABA combination therapy or other add-on treatments. Amy has mild asthma, so prescribing omalizumab would be premature and inappropriate. Additionally, the use of omalizumab requires specific evaluations, including measuring serum IgE levels and confirmation of allergic asthma.

You are correct that a beta-2 agonist would be beneficial for Amy. Salbutamol, is a short-acting drug and it is normally used in acute settings or as needed, rather than for chronic treatment.

I encourage you to revisit the guidelines for initial asthma management and think about which treatments address both symptom relief and inflammation.